Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Biochemistry (Paediatric)
  6. Management of symptomatic hyponatraemia, paediatrics (190)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Management of symptomatic hyponatraemia, paediatrics (190)

Warning

Algorithm

Hyponatraemia treatment algorithm - flowchart

Definition

Hyponatraemia is defined as plasma sodium <135mmol/L. There is an excess of water relative to sodium in the extracellular fluid compartment, due to an excess of water, a deficit of sodium or more commonly a combination of both.  Acute hyponatraemia is arbitrarily defined as < 48 hours duration.

Background

  • Hyponatremia is the commonest electrolyte abnormality in paediatrics.
  • Symptoms of hyponatremia are dependent upon the severity of hyponatremia (mild – Se. Na+ 130 –135, Moderate – Se. Na+ 120 – 130, Severe – Se. Na+ < 120) and rate of development (acute < 48 hrs. vs chronic > 48 hrs.).
  • Serum sodium measurement is altered by lipaemia and as such in these patients, Blood Gas analyzer electrodes may be more accurate than lab analyzer.
  • Most cases of hyponatraemia are mild and these children are mostly asymptomatic
  • Symptoms are more likely when hyponatremia has developed acutely or is severe. This is because the brain has a time-limited ability to cope with the accompanying change in plasma tonicity.
  • Hyponatremia symptoms are mainly due to cerebral edema and include seizures, altered consciousness, Apneas, headache, nausea and vomiting. Hyponatremic seizures may be resistant to normal anticonvulsant therapy.
  • Children have reduced capacity to adapt to hypotonicity as they have a higher brain:skull volume ratio, higher brain water content, a proportionately smaller intra-cerebral CSF volume and higher cerebral intracellular sodium content than adults. As such they are prone to symptoms at higher sodium levels and earlier during a fall in serum sodium.
  • Common causes in children include
    • GI fluid loss that was replaced with hypotonic solution
    • SIADH (hospitalized patients on fluid therapy)
    • Increased Total body water with reduced effective circulating volume (Heart failure, nephrotic syndrome)
    • severe Kidney injury with impaired water excretion.
  • Assessment of volume status is key in identifying the etiology and directing therapy.

Principles of therapy

  • Goals of management:
    • Relieve the symptoms of hyponatremia.
    • Avoid too rapid correction to prevent CNS complications
    • Prevent a further decline in sodium concentration
  • In asymptomatic children with mild hyponatraemia, the goal is to identify and treat the underlying condition causing hyponatraemia to prevent further fall in serum sodium levels.
  • During correction of symptomatic hyponatraemia patients should be managed in a setting where adequate frequent detailed assessment can occur- ideally an HDU or PICU but such transfer should not delay institution of therapy.
  • During correction, fluid balance and biochemical data should be repeatedly assessed to ensure that correction of hyponatraemia is occurring at a controlled rate.
  • Hypertonic saline (2.7%) can be safely used via peripheral route in symptomatic patients.
  • The suggested standard dose is 3 mls/kg of body weight and the rate of administration will depend on the severity of symptoms. (see Flowchart)
  • 1ml/kg 2.7% sodium chloride will increase serum sodium by approximately 0.8mmol/l.
  • Repeat boluses of 2.7% sodium chloride can be used to control symptoms during correction.
  • Once patients are asymptomatic, the rate of correction should be slowed down to target an ideal increase of 6-8 meq/l in serum sodium over the next 24 hours.
  • This can be achieved with reducing the tonicity of the IV fluid and the rate of infusion.
  • Osmotic demyelination syndrome is a very rare condition associated with rapid correction of chronic hyponatraemia. Use caution in these patients and stop infusion of 2.7 % sodium chloride as soon as symptoms resolve
  • Further IV Fluid therapy is dictated by the underlying etiology of hyponatraemia.

Contact for further advice

PICU duty registrar: Staff base 1 - Beds 1-12 PICU

Editorial Information

Last reviewed: 27/11/2024

Next review date: 31/12/2027

Author(s): Anne Mcgettrick, Colin Begg, Graham Bell, Mohammed Uvaise.

Version: 5

Author email(s): graham.bell6@nhs.scot.

Approved By: RHC IV Fluid Group

Document Id: 190

References
  1. Somers MJ, Traum AZ. Hyponatremia in children: Evaluation and management. UpToDate. 2024.
  2. Brossier D.W., Tume L.N., Briant A.R., et al. ESPNIC clinical practice guidelines: intravenous maintenance fluid therapy in acute and critically ill children- a systematic review and meta-analysis. Intensive Care Med. 2022;48(12):1691–708.
  3. Royal Children’s Hospital, Melbourne. Last updated 2023. Clinical practice guidelines: hyponatraemia
  4. Mazzolai M., Apicella A., Marzuillo P., et al. Severe hyponatremia in children: A review of the literature through instructive cases. Minerva Pediatr. 2022;74(1):61–9.